Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating colonitis

A technology for colitis and ulcerative colitis, applied in the field of medicine, can solve problems such as large dosage of drugs, doubtful value of immunosuppressants, obvious side effects, etc., and achieve the effect of enhancing therapeutic effect, overcoming large side effects, and reducing toxic and side effects

Pending Publication Date: 2020-02-04
镇江星盘商务咨询有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

③The value of immunosuppressants in ulcerative colitis is still doubtful
[0006] At present, the drugs used to treat colitis, especially ulcerative colitis, have problems such as large dosage and obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating colonitis
  • Medicine for treating colonitis
  • Medicine for treating colonitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Effect of combined application of racemic anisodamine and neostigmine on disease activity index in mice with ulcerative colitis

[0027] The test drugs racemic anisodamine and neostigmine were divided into three groups (n=10): 5 mg / kg racemic anisodamine and 10 μg / kg neostigmine, 10 mg / kg racemic anisodamine and 20 μg / kg neostigmine, 20 mg / kg racemic anisodamine and 40 μg / kg neostigmine. From the third day of modeling (feeding drinking water containing 3% DSS), racemic anisodamine and neostigmine were administered twice a day. The normal group was given an equal volume of normal saline orally, and drank water normally.

[0028] The model of ulcerative colitis was induced in the mice by feeding water with 3% DSS, and then treated with racemic anisodamine and neostigmine according to the above doses and methods respectively, and then the state of the mice was observed every day.

[0029] The disease activity index (DAI) was assessed as follows: DAI is the sum...

Embodiment 2

[0031] Embodiment 2 Effects of racemic anisodamine and neostigmine combined application on body weight of mice with ulcerative colitis

[0032] Test drugs, mouse model construction, and administration methods are the same as in Example 1.

[0033] The body weight on the first day was taken as 100%, and the change in body weight on this basis was calculated as a percentage.

[0034] The result is as figure 2 As shown, the body weight of mice continued to decrease after DSS modeling, and 10 mg / kg racemic anisodamine and 20 μg / kg neostigmine, 20 mg / kg racemic anisodamine and 40 μg / kg neostigmine could all reduce body weight The degree of decline, of which 20mg / kg racemic anisodamine and 40μg / kg neostigmine effect is better.

Embodiment 3

[0035] Example 3 Effect of combined application of racemic anisodamine and neostigmine on colon length in mice with ulcerative colitis

[0036] Test drugs, mouse model construction, and administration methods are the same as in Example 1.

[0037] After 7 days, the mice were sacrificed, and the colons were removed and measured for length.

[0038] The result is as Figure 3-4 As shown, DSS modeling can cause colon inflammation, intestinal wall thinning, and finally lead to shortened colon length, 10mg / kg racemic anisodamine and 20μg / kg neostigmine, 20mg / kg racemic anisodamine and 40μg Neostigmine / kg neostigmine can inhibit the shortening of the colon to varying degrees, among which 20mg / kg racemic anisodamine and 40μg / kg neostigmine have significant effects.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating colonitis, and belongs to the technical field of medicines. The invention discloses the medicine for treating colonitis. According to the medicine, themass ratio of racanisodamine and neostigmine is 500:1; and the racanisodamine is used as a traditional medicine, is simple and convenient in synthetic method, is easy to get, and is combined with theneostigmine for application so as to be improved in therapeutical effect and reduced in toxic and side effects, so that the defect of severe side effects caused by the independent application of a medicine is overcome. The medicine for treating colonitis provided by the invention provides a new means for the clinic treatment of colonitis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a medicine for treating colitis. Background technique [0002] Racemic anisodamine, chemical name: (±)-6β-hydroxy-1αH, 5αH-tropane-3α-alcohol tropic acid ester, drug alias: 654, 654-1, 654-2, English name: Anisodamine, Molecular formula C 17 h 23 NO 4 , molecular weight 305.38. Like atropine, it belongs to cholinergic receptor blockers, but compared with atropine, anisodamine has weaker pharmacological effects, lower toxicity and adverse reactions, so it is more commonly used clinically than atropine. Anisodamine can relax smooth muscle and relieve vasospasm, and can be used to treat ① toxic shock of infection: such as fulminant meningitis, toxic dysentery, etc. (to be used in combination with antibiotics); ② vascular diseases: cerebral thrombosis , cerebral embolism, paralysis, cerebral vasospasm, angioneurotic headache, thromboangiitis obliterans, etc.; ③ various neuralgi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/46A61K31/27A61P1/00A61P1/04
CPCA61K31/46A61K31/27A61P1/00A61P1/04
Inventor 刘冲张静静
Owner 镇江星盘商务咨询有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com